Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients

By Sharma Amit   Ketteler Markus   Marshall Thomas S.   Khan Samina S.   Schumock Glen T.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1129-1136

Informa Healthcare

Access to resources Recommend Favorite

Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism

By  

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 3, 2015-06 ,pp. : 225-234

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cinacalcet Improves Endothelial Dysfunction and Cardiac Hypertrophy in Patients on Hemodialysis with Secondary Hyperparathyroidism

By  

Nephron Clin Pract, Vol. 122, Iss. 1-2, 2013-03 ,pp. : 1-8

Karger

Access to resources Recommend Favorite

Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A German-Austrian, Single-Arm, Open-Label, Prospective, Noninterventional, Observational Study

By  

Nephron Clin Pract, Vol. 126, Iss. 1, 2014-01 ,pp. : 39-50

Karger

Access to resources Recommend Favorite

Impact of Vitamin D Dose on Biochemical Parameters in Patients with Secondary Hyperparathyroidism Receiving Cinacalcet

By  

Nephron Clin Pract, Vol. 112, Iss. 1, 2009-04 ,pp. : c41-c50

Karger

Access to resources Recommend Favorite